Lyell Immunopharma Net Tangible Assets

The latest net tangible assets for LYEL is $230M as of June 2026. That compares with $300M in the prior-year period — down 21.8% year over year. Investors often review this figure alongside Lyell Immunopharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, LYEL's net tangible assets moved from $300M to $230M — a 21.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lyell Immunopharma's operating scale or balance-sheet position.

A net tangible assets figure of $230M for LYEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting LYEL's net tangible assets ($230M), review year-over-year change from $300M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lyell Immunopharma's net tangible assets against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.